<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03969121</url>
  </required_header>
  <id_info>
    <org_study_id>OOTR-N016/KBCRN-B-003/HT-PAB</org_study_id>
    <nct_id>NCT03969121</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer</brief_title>
  <official_title>A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto Breast Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyoto Breast Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the
      primary objective of demonstrating the efficacy of palbociclib in combination with Endocrine
      therapy over Endocrine therapy alone measured by PEPI and EndoPredict™ EPclin Score in women
      with operable HR+, HER2 negative breast cancer . The Clinical Response Rate, drop in Ki67
      index ≤ 2.7% and Breast conserving rate will be compared between two arms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-operative Endocrine Prognostic Index (PEPI Score)</measure>
    <time_frame>4 months</time_frame>
    <description>The PEPI score is derived from four factors assigned a numerical score following neoadjuvant endocrine therapy, ( including Ki67 expression in the surgical specimen, pathologic tumor size, lymph node status, and estrogen receptor (ER) level).
The PEPI score is the sum of each component score and shows the risk points for relapse-free survival. PEPI=0 means low risk. PEPI= 1 to 3 means intermediate risk .
PEPI more than 4 means high risk.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EndoPredict™ EPclin Score</measure>
    <time_frame>4 months</time_frame>
    <description>EndoPredict is a multigene test used to predict the risk of distant recurrence of early stage, ER positive ,HER-2 Negative invasive breast cancer. EndoPredict Clinical Score (EP clin ) categorizes patinets into low and high risk groups.Combination of the 12-Gene Molecular Score, tumor stage and lymph node status, generating an EPclin Risk Score.The EPclin Risk Score is calculated, according to the model, as:
EPclin Risk Score = (0.35 * tumor size) + (0.64 * lymph node status) + (0.28 * 12-Gene Molecular Score) EPclin Risk Scores from 1.0 through 3.3 shows low risk of recurrencein 10 years.EPclin Risk Scores from 3.4 through 6.0 shows high risk of recurrence in 10 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate</measure>
    <time_frame>4 months</time_frame>
    <description>Observing any reduction in largest tumor diameter on clinical breast examination and ultrasound imaging of breast and axilla after 4 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ki67 change</measure>
    <time_frame>4 months</time_frame>
    <description>Drop in Ki67 index to less than or equal to 2.7%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological response rate</measure>
    <time_frame>4 months</time_frame>
    <description>Evaluating the rate of pathological Complete Response based on assessment of surgical specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast conserving rate</measure>
    <time_frame>4 months</time_frame>
    <description>Calculating the rate of breast conserving surgery based on the number of each surgery type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment as Assessed by CTCAE v4.03</measure>
    <time_frame>4 months</time_frame>
    <description>Type, incidence, severity (as graded by National Cancer Institute - Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03), seriousness and relationship to study medications of adverse events (AE) and any laboratory abnormalities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Hormone Receptor Positive Malignant Neoplasm of Breast</condition>
  <arm_group>
    <arm_group_label>Placebo + Endocrine therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endocrine therapy for 16 weeks plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palbociclib + Endocrine therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endocrine therapy for 16 weeks plus Palbociclib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment</description>
    <arm_group_label>Palbociclib + Endocrine therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine therapy</intervention_name>
    <description>Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.</description>
    <arm_group_label>Palbociclib + Endocrine therapy</arm_group_label>
    <arm_group_label>Placebo + Endocrine therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pre/peri- or post-menopausal women 18 years and older (or local legal age, whichever
             is higher)

          2. Primary tumor greater than 2 cm in diameter

          3. Histologically proven invasive breast cancer

          4. Positive hormone receptor (ER and/or PgR ≥ Allred 3)

          5. Negative HER-2 receptor

          6. Ki67 index equal to or greater than 14% (Ki67 ≥ 14%) by central assessment

          7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1 or Karnofsky
             performance status ≥ 70%

          8. No previous history of radiotherapy or systemic therapy including chemotherapy and
             hormone therapy for breast cancer

          9. Laboratory values must be as follows:

             Absolute neutrophil count: ≥ 1,500/mm3

             Platelets: ≥ 100,000/mm3

             Hemoglobin: ≥ 9 g/dL

             Bilirubin: ≤ 1.5 × upper limits of normal (ULN)

             Serum Creatinine: ≤ 1.5 × ULN

             Alkaline phosphatase: ≤ 2 × ULN

             AST and ALT: ≤ 2 × ULN

             Cardiac function: Normal finding of Electrocardiogram (ECG) QTc ≤ 480 msec (based on
             the mean value of the triplicate ECGs).

         10. Able to give written informed consent form

         11. Willingness and ability to comply with scheduled visits, treatment plan, laboratory
             tests, and other study procedures

        Exclusion Criteria:

          1. Male

          2. Locally advanced breast cancer (T3N1 or Any T4 or Any N2, N3), or distant me-tastasis

          3. Multicentric breast cancer (Note: Multifocal breast cancer,located in one quadrant/are
             is eligible)

          4. Prior treatment with chemotherapy, radiotherapy and/or endocrine therapy

          5. Previous use of SERMs such as raloxifene.

          6. Prior therapy with any CDK4/6 inhibitor or with everolimus, or any agent whose
             mechanism of action is to inhibit the PI3K-mTOR pathway.

          7. Prior history of other malignancy within 5 years of study entry, aside from basal cell
             carcinoma of the skin or carcinoma-in-situ of the uterine cervix

          8. Major surgery within 3 weeks of first study treatment

          9. Patients treated within the last 7 days prior to randomization with:

               -  Food or drugs that are known strong and moderate CYP3A4 inhibitors (e.g.,
                  amprenavir, aprepitant, atazanavir, boceprevir, casopitant, cimetidine,
                  ciprof-loxacin, clarithromycin, conivaptan, cobicistat, crizotinib, cyclosporine,
                  da-runavir, diltiazem, dronedarone, elvitegravir, erythromycin, fluconazole,
                  fosamprenavir, imatinib, indinavir, isavuconazole, istradefylline,
                  itraconazole,ketoconazole, letermovir, lopinavir, mibefradil, miconazole,
                  nefazodone, nelfinavir, nilotinib, posaconazole, ritonavir, saquinavir,
                  schisandra sphenan-thera extract, telaprevir, telithromycin, tofisopam,
                  verapamil, voriconazole, and grapefruit, grapefruit juice or any product
                  containing grapefruit);

               -  Drugs that are known strong and moderate CYP3A4 inducers (e.g., bosentan,
                  carbamazepine, efavirenz, etravirine, modafinil, phenobarbital, phenytoin,
                  ri-fampin, rifapentin, and St. John's wort);

         10. Any of the following in the previous 6 months of randomization: myocardial
             in-farction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE version
             4.03 grade ≥ 2, atrial fibrillation of any grade, coronary/peripheral artery bypass
             graft, symptomatic congestive heart failure, cerebrovascular accident in-cluding
             transient ischemic attack, or symptomatic pulmonary embolism

         11. Family or personal history of long or short QT syndrome, Brugada syndrome or known
             history of QTc prolongation, or Torsade de Pointes (TdP).

         12. Uncontrolled electrolyte disorders (eg, hypocalcemia, hypokalemia, hypomag-nesemia)
             that can compound the effects of a QTc-prolonging drug.

         13. Active inflammatory bowel disease or chronic diarrhea. Short bowel syndrome. Upper
             gastrointestinal surgery including gastric resection.

         14. Prior hematopoietic stem cell or bone marrow transplantation.

         15. Known abnormalities in coagulation such as bleeding diathesis, or treatment with
             anticoagulants precluding subcutaneous injections of leuprorelin or goserelin.

         16. Hepatitis B and/or hepatitis C carriers (unless with normal hepatic function)

         17. Known human immunodeficiency virus (HIV) infection

         18. Known hypersensitivity to anti-aromatase drugs, tamoxifen or any cell cycle
             in-hibitor.

         19. Patients who are pregnant or lactating. Patients of childbearing potential and/or her
             partner who are unwilling or unable to use a method of highly effective non-hormonal
             contraception throughout the study and continue for at least 21 days in patients after
             the last dose of investigational drug.

         20. Other severe acute or chronic medical or psychiatric condition, or laboratory
             ab-normality that would impart, in the judgment of the investigator, excess risk
             as-sociated with study participation or study drug administration, or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study

         21. Patients who are investigational site staff members or relatives of those site staff
             OOTR-N016/KBCRN-B-003/HT-PAB Protocol (version 1.2 dated Oct 11, 2018) 24 members or
             patients who are the sponsor employees directly involved in the con-duct of the trial.

         22. Participation in other studies involving investigational drug (s) (Phases 1-4) within
             2 weeks before randomization and/or until a visit at 4 weeks (+7 days) after
             operation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masakazu Toi, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyoto University, Professor of Breast Surgery Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis WC Chow, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Organisation for Oncology and Translational Research (OOTR)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takayuki Ueno, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute Hospital of JFCR, Department Director, Breast Surgical Oncology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elham Fakhrejahani, MD,PhD</last_name>
    <phone>0755857861</phone>
    <email>kbcrn-b-003@kyoto-breast-cancer.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Brooks</last_name>
      <phone>61 3 8572 2393</phone>
      <email>Christine.Brooks@monashhealth.org</email>
    </contact>
    <investigator>
      <last_name>Michelle White, MBBS, GDipPallMed, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruce Mann, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard de Boer, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNIMED Medical Institute</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohong Lu</last_name>
      <phone>852-2861-0286</phone>
      <email>xhlu@tremed.org</email>
    </contact>
    <investigator>
      <last_name>Louis W.C. Chow, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amagasaki General Medical Center</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hirofumi Suwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hiroko Bando, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sawako Saito</last_name>
      <phone>092-541-3231</phone>
    </contact>
    <investigator>
      <last_name>Eriko Tokunaga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sagara Hospital</name>
      <address>
        <city>Kagoshima</city>
        <zip>892-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miho Sakaguchi</last_name>
      <phone>099-224-1800</phone>
    </contact>
    <investigator>
      <last_name>Masahiro Kashiwaba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yuichiro Kikawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mao Kuratani</last_name>
      <phone>075-751-4389</phone>
    </contact>
    <investigator>
      <last_name>Masahiro Takada, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masakazu Toi, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Nagoya</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siji Oshima</last_name>
      <phone>(052)762-6111</phone>
    </contact>
    <investigator>
      <last_name>Hiroji Iwata, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tazuke Kofukai, Medical Research Institute, Kitano Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sachiko Takahara, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Saitama</city>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiyaki Moriya</last_name>
      <phone>048-722-1111</phone>
    </contact>
    <investigator>
      <last_name>Kenichi Inoue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiyomi Nonogaki</last_name>
      <phone>03-3588-1111</phone>
    </contact>
    <investigator>
      <last_name>Toshimi Takano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Komagome Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miyabi Oe</last_name>
      <phone>03-3823-2101</phone>
    </contact>
    <investigator>
      <last_name>Tomoyuki Aruga, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital Of JFCR</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akemi Matsui</last_name>
      <phone>03(3570)0208</phone>
    </contact>
    <investigator>
      <last_name>Takayuki Kobayashi, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takayuki Ueno, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shigeru Imoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rie Hirasawa</last_name>
      <phone>045-520-2222</phone>
    </contact>
    <investigator>
      <last_name>Toshinari Yamashita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eun Sook Lee, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jee Hyun Kin, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hyun Ah Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wonshik Han, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seock-Ah Im, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Min-Hyuk Lee, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aju University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yongsik Jung, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shou-Tung Chen, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ming-Feng Hou, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chiun-Sheng Huang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Cancer Center</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mei-Ching Liu, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Palbociclib</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>PEPI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

